Glaukos COO Gilliam exercises options, sells 44,917 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Glaukos Corp (GKOS) President & COO Joseph E. Gilliam exercised options for 44,917 common shares on November 12, 2026. The five reported option lots were 2,475 shares at $69.30, 7,500 shares in each of two lots at $48.46, and 11,250 and 16,192 shares at $55.18 per share.
Gilliam also sold 44,917 shares in six transactions that day; reported weighted-average sale prices ranged from $243.41 to $248.42 per share. The option exercises and sales were effected pursuant to a Rule 10b5-1 trading plan.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F9, F10 | 2,475 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F9, F10 | 7,500 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F9, F11 | 7,500 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F9, F12 | 11,250 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F9, F13 | 16,192 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 2,475 | $69.30 | $172K |
| Exercise | Common Stock F1 | 7,500 | $48.46 | $363K |
| Exercise | Common Stock F1 | 11,250 | $55.18 | $621K |
| Exercise | Common Stock F1 | 16,192 | $55.18 | $893K |
| Exercise | Common Stock F1 | 7,500 | $48.46 | $363K |
| Sale | Common Stock F2, F3, F1 | 2,402 | $243.41 | $585K |
| Sale | Common Stock F2, F4, F1 | 3,700 | $244.49 | $905K |
| Sale | Common Stock F2, F5, F1 | 8,015 | $245.77 | $1.97M |
| Sale | Common Stock F2, F6, F1 | 18,440 | $246.49 | $4.55M |
| Sale | Common Stock F2, F7, F1 | 12,060 | $247.50 | $2.98M |
| Sale | Common Stock F2, F8, F1 | 300 | $248.42 | $75K |
Footnotes (13)
- F1. Includes 40,039 restricted stock units that have not yet vested or been delivered to the Reporting Person.
- F2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2026.
- F3. This transaction was executed in multiple trades at prices ranging from $242.96 to $243.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $244.00 to $245.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $245.06 to $246.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $246.07 to $247.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $247.08 to $248.08. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8. This transaction was executed in multiple trades at prices ranging from $248.34 to $248.46. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9. The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2026.
- F10. These options vest over four years from the grant date, with 25% vesting on the first anniversary of the grant date and the remaining amount vesting in equal monthly installments over the following three years.
- F11. Represents a portion of an option to purchase shares of common stock previously granted by the Issuer on March 22, 2023, the vesting of which was subject to the Issuer's achievement of certain pre-determined operational targets over a multi-year performance period.
- F12. Represents a portion of an option to purchase shares of common stock previously granted by the Issuer to the Reporting Person on March 24, 2022 in connection with his promotion to President and Chief Operating Officer, the vesting of which was subject to the Issuer's achievement of certain multi-year performance goals.
- F13. Represents a portion of an option to purchase shares of common stock previously granted by the Issuer on March 24, 2022, the vesting of which was subject to the Issuer's achievement of certain pre-determined operational targets over a multi-year performance period.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
weighted average price financial
restricted stock units financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Were the GKOS option exercises and sales made under a trading plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.